Search results for "tumor suppressor gene"

showing 10 items of 98 documents

Definitive evidence for Club cells as progenitors for mutantKras/Trp53‐deficient lung cancer

2021

Accumulating evidence suggests that both the nature of oncogenic lesions and the cell-of-origin can strongly influence cancer histopathology, tumor aggressiveness and response to therapy. Although oncogenic Kras expression and loss of Trp53 tumor suppressor gene function have been demonstrated to initiate murine lung adenocarcinomas (LUADs) in alveolar type II (AT2) cells, clear evidence that Club cells, representing the second major subset of lung epithelial cells, can also act as cells-of-origin for LUAD is lacking. Equally, the exact anatomic location of Club cells that are susceptible to Kras transformation and the resulting tumor histotype remains to be established. Here, we provide de…

Cancer ResearchLung NeoplasmsLineage (genetic)Tumor suppressor geneCell of originAdenocarcinomaBiologymedicine.disease_causeMicemedicineAnimalsHumansProgenitor cellLung cancerLungMice KnockoutLungCancerEpithelial Cellsmedicine.diseaseGene Expression Regulation NeoplasticMice Inbred C57BLCell Transformation NeoplasticGenes rasmedicine.anatomical_structureOncologyMutationDisease ProgressionCancer researchKRASTumor Suppressor Protein p53International Journal of Cancer
researchProduct

Expression of Hugl-1 is strongly reduced in malignant melanoma.

2005

The human gene Hugl-1 (Llgl/Lgl1) has significant homology to the Drosophila tumor suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that is involved in maintaining cell polarity and epithelial integrity. We speculate that Hugl-1 might play a role in epithelial-mesenchymal transition (EMT) and that loss of Hugl-1 expression plays a role in the development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of Hugl-1 transcription. We found that Hugl-1 was downregulated or lost in all cell lines and in most of the tumor samples analysed, and that these losses wer…

Cancer ResearchMMP2Tumor suppressor geneMatrix Metalloproteinases Membrane-AssociatedTranscription GeneticCellBlotting WesternDown-RegulationBiologyTransfectionEpitheliumCell MovementCell Line TumorGeneticsmedicineCell AdhesionMatrix Metalloproteinase 14HumansNeoplasm InvasivenessTissue DistributionRNA MessengerCell adhesionMolecular BiologyMelanomaReverse Transcriptase Polymerase Chain ReactionMelanomaProteinsCell migrationmedicine.diseaseCadherinsImmunohistochemistryMatrix MetalloproteinasesGene Expression Regulation NeoplasticCytoskeletal Proteinsmedicine.anatomical_structureMicroscopy FluorescenceCell cultureImmunologyCancer researchDisease ProgressionMMP14Matrix Metalloproteinase 2RNAOncogene
researchProduct

Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis

2001

Metallothioneins (MTs) and glutathione constitute the major fractions of intracellular thiol factors. Abundant nucleophilic sulfhydryl groups can interact with many electrophilic substances, including several anti-neoplastic agents, participate in controlling intracellular redox potential, and act as scavengers of reactive oxygen species. In the present study, we examined the relation of MTs (alone and in combination with glutathione) to histopathological parameters and survival time of ovarian cancer patients. Expression of the major MT isoforms (MT-1 and MT-2) was determined by immunohistochemistry on paraffin-embedded tumor specimens from 189 patients, 151 suffering from primary epitheli…

Cancer ResearchPathologymedicine.medical_specialtyTumor suppressor geneProportional hazards modelOvaryGlutathioneBiologymedicine.diseaseAndrologychemistry.chemical_compoundmedicine.anatomical_structureOncologychemistrymedicineImmunohistochemistryMetallothioneinHistopathologyOvarian cancerInternational Journal of Cancer
researchProduct

Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediatedviathe extrinsic and the intrinsic pathway

2010

We investigated the downstream mechanisms by which chemotherapeutic drugs elicit apoptosis in hepatocellular carcinoma (HCC). Genomic signatures of HCC cell lines treated with different chemotherapeutic drugs were obtained. Analyses of apoptosis pathways were performed and RNA interference was used to evaluate the role of the p53 family. Endogenous p53, p63 and p73 were upregulated in response to DNA damage by chemotherapeutic drugs. Blocking p53 family function led to chemoresistance in HCC. Stimulation and blocking experiments of the CD95-, the TNF- and the TRAIL-receptor systems revealed that cytotoxic drugs, via the p53 family members as transactivators, can trigger expression of each o…

Cancer ResearchProgrammed cell deathCarcinoma HepatocellularTumor suppressor geneDNA damagetumor suppressor protein p53membrane proteinsoligonucleotide array sequence analysiscarcinomaBiologyhepatocellularfas-associated death domain proteinAPAF1humansMembrane Potential Mitochondrialhep G2 cellsbleomycinliver neoplasmsSettore BIO/11apoptosisPrognosismitochondrialFas receptorcaspasesOncologyApoptosisbiology.proteinCancer researchMdm2membrane potentialSignal transductionPrognosis; bleomycin; caspases; membrane potential mitochondrial; oligonucleotide array sequence analysis; tumor suppressor protein p53; membrane proteins; fas-associated death domain protein; humans; liver neoplasms; hep G2 cells; apoptosis; carcinoma hepatocellularInternational Journal of Cancer
researchProduct

IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.

2009

Abstract IFNs are pleiotropic cytokines that have been shown to be important regulators of cell growth. IFN-α has recently been recognized to harbor therapeutic potential in prevention and treatment of hepatocellular carcinoma (HCC). However, HCC cells respond differentially to IFN treatment, the mechanism of which is largely unknown. To address this issue, we analyzed the effect of IFN-α on different liver tumor cell lines. We found that growth inhibiting effects of IFN-α in hepatoma cells require PML-NB induction and, moreover, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) expression on the mRNA and protein level. RNAi silencing of PML down-regulates TRAIL expression in …

Cancer ResearchProgrammed cell deathCarcinoma HepatocellularTumor suppressor genemedicine.medical_treatmentApoptosisPromyelocytic Leukemia ProteinTNF-Related Apoptosis-Inducing LigandPromyelocytic leukemia proteinMiceCell Line TumormedicineGene silencingAnimalsHumansRNA MessengerbiologyCell growthTumor Suppressor ProteinsLiver NeoplasmsInterferon-alphaNuclear ProteinsCytokineOncologyApoptosisbiology.proteinCancer researchTumor necrosis factor alphaRNA InterferenceTumor Suppressor Protein p53Transcription FactorsCancer research
researchProduct

The p53 Tumor Suppressor Network Is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress

2005

Abstract Activation of the p53 network plays a central role in the inflammatory stress response associated with ulcerative colitis and may modulate cancer risk in patients afflicted with this chronic disease. Here, we describe the gene expression profiles associated with four microenvironmental components of the inflammatory response (NO•, H2O2, DNA replication arrest, and hypoxia) that result in p53 stabilization and activation. Isogenic HCT116 and HCT116 TP53−/− colon cancer cells were exposed to the NO• donor Sper/NO, H2O2, hypoxia, or hydroxyurea, and their mRNA was analyzed using oligonucleotide microarrays. Overall, 1,396 genes changed in a p53-dependent manner (P < 0.001), wit…

Cancer ResearchTumor suppressor geneColorectal cancerInflammationBiologymedicine.disease_causeArticleGene expressionmedicineHumansNitric Oxide DonorsInflammationReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCell CycleHydrogen PeroxideCell cycleHypoxia (medical)Flow CytometryHCT116 Cellsmedicine.diseaseCell HypoxiaGene expression profilingOxidative StressOncologyImmunologyNitrogen OxidesSpermineTumor Suppressor Protein p53medicine.symptomOxidative stressCancer Research
researchProduct

Functional analysis ofp53 gene and the prognostic impact of dominant-negativep53 mutation in endometrial cancer

2005

In addition to the loss of function, mutant p53 can possess a dominant-negative effect on wild-type p53 and may also exert gain-of-function activity. It is not clear whether the functional status of p53 mutation contributes to differences in outcome in endometrial cancer. We collected a total of 92 RNA samples of high quality from endometrial cancer tissues, and the samples were subjected to yeast functional assay and sequencing for p53 mutations. The detected mutant p53 genes were further investigated for their dominant-negative activity using a yeast-based transdominance assay. p53 mutation was found in 24 out of 92 (26.1%) tumors, of which 10 exhibited no dominant-negative activity (rece…

Cancer ResearchTumor suppressor geneDNA Mutational AnalysisMutantBiologyYeastsmedicineHumansStage (cooking)GeneLoss functionNeoplasm StagingEndometrial cancerRNAMiddle AgedGenes p53Prognosismedicine.diseaseSurvival AnalysisEndometrial NeoplasmsOncologyMultivariate AnalysisMutation (genetic algorithm)Cancer researchRNABiological AssayFemaleInternational Journal of Cancer
researchProduct

The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma.

1997

FHIT (Fragile Histidine Triad), a putative tumor suppressor gene, was cloned from fetal brain and colon cDNA libraries. Portions of this gene are deleted in esophageal, colon, lung and breast tumors, but this gene has not been found altered in sporadic renal cell carcinomas. We report here an alternatively spliced form of this gene cloned from a kidney cDNA library. This cDNA is 1189 bp in length, and contains an additional 94 bp exon, designated exon 2a (E2a). This novel sequence is located between exon 2 and exon 3 of the FHIT gene's untranslated region and exon 2a is present in all normal kidney tissues and cell lines. Analyses performed on sporadic renal cell carcinoma (RCC) tissues and…

Cancer ResearchTumor suppressor geneMolecular Sequence DataBiologymedicine.disease_causeKidneyPolymerase Chain ReactionExonFHITComplementary DNAGene expressionGeneticsmedicineHumansGenes Tumor SuppressorAmino Acid SequenceCloning MolecularneoplasmsMolecular BiologyCarcinoma Renal CellBase SequencecDNA libraryAlternative splicingProteinsBlotting NorthernKidney NeoplasmsAcid Anhydride HydrolasesNeoplasm ProteinsAlternative SplicingCancer researchCarcinogenesisOncogene
researchProduct

Loss of tumor suppressor protein PTEN during renal carcinogenesis

2002

The tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) encodes a dual specific protein and phospholipid phosphatase that affects cell proliferation, apoptosis and migration. In our study, we examined protein expression of PTEN in renal carcinogenesis. PTEN protein levels were examined in 42 clear cell renal cell carcinomas (ccRCC) and oncocytomas as well as in the corresponding normal renal tissue of the same patients using Western blot analysis. Cellular localization was analyzed by immunohistochemistry. PTEN was highly expressed in all investigated normal renal tissue specimens. Immunohistochemical analysis showed an almost exclusive staining of proxi…

Cancer ResearchTumor suppressor genebiologyurologic and male genital diseasesmedicine.disease_causeBlotOncologymedicineCancer researchbiology.proteinTensinPTENCarcinogenesisImmunostainingClear cellCellular localizationInternational Journal of Cancer
researchProduct

Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues.

2001

PTEN, a tumour suppressor gene located at chromosome 10q23 and commonly mutated or deleted in a variety of tumours, encodes a dual-specific/phosphatidylinositol-3,4,5-triphosphate (PIP3) phosphatase. We report the generation of an anti-PTEN monoclonal antibody (MAb) that recognises an epitope at the C-terminus of PTEN, and describe the heterogeneous lack of expression of the PTEN protein in human tumour tissues, as demonstrated by immunohistochemical methods. Our anti-PTEN MAb provides a useful tool for the study of PTEN protein expression in tumour samples, in the search for tumour prognostic molecular markers.

Cancer ResearchTumor suppressor genemedicine.drug_classMonoclonal antibodyEpitopelaw.inventionMicelawNeoplasmsGene expressionmedicineTumor Cells CulturedPTENAnimalsHumansMice Inbred BALB CbiologyTumor Suppressor ProteinsPTEN PhosphohydrolaseCancerAntibodies Monoclonalmedicine.diseaseMolecular biologyImmunohistochemistryPhosphoric Monoester HydrolasesNeoplasm ProteinsOncologybiology.proteinCancer researchSuppressorImmunohistochemistryEuropean journal of cancer (Oxford, England : 1990)
researchProduct